PL1680426T3 - Pochodne 1,3,4-triazafenalenu i 1,3,4,6-tetraazafenalenu - Google Patents
Pochodne 1,3,4-triazafenalenu i 1,3,4,6-tetraazafenalenuInfo
- Publication number
- PL1680426T3 PL1680426T3 PL04729442T PL04729442T PL1680426T3 PL 1680426 T3 PL1680426 T3 PL 1680426T3 PL 04729442 T PL04729442 T PL 04729442T PL 04729442 T PL04729442 T PL 04729442T PL 1680426 T3 PL1680426 T3 PL 1680426T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- phenalene
- triaza
- treatment
- control
- Prior art date
Links
- YPJREQDHTKXDDE-UHFFFAOYSA-N 2,4,6,8-tetrazatricyclo[7.3.1.05,13]trideca-1(13),2,4,6,9,11-hexaene Chemical class N1=CNC2=CC=CC3=NC=NC1=C32 YPJREQDHTKXDDE-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- MMFGLLRFTDSLPQ-UHFFFAOYSA-N 2,4,6-triazatricyclo[7.3.1.05,13]trideca-1(12),3,5,7,9(13),10-hexaene Chemical compound N1=CNC2=CC=CC3=CC=NC1=C32 MMFGLLRFTDSLPQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47731803P | 2003-06-10 | 2003-06-10 | |
| EP04729442A EP1680426B1 (en) | 2003-06-10 | 2004-04-26 | 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives |
| PCT/EP2004/050608 WO2004111055A1 (en) | 2003-06-10 | 2004-04-26 | 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1680426T3 true PL1680426T3 (pl) | 2008-02-29 |
Family
ID=33551702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04729442T PL1680426T3 (pl) | 2003-06-10 | 2004-04-26 | Pochodne 1,3,4-triazafenalenu i 1,3,4,6-tetraazafenalenu |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7217717B2 (pl) |
| EP (1) | EP1680426B1 (pl) |
| JP (1) | JP2006527235A (pl) |
| KR (1) | KR100753385B1 (pl) |
| CN (1) | CN100378101C (pl) |
| AT (1) | ATE373661T1 (pl) |
| AU (1) | AU2004247418B2 (pl) |
| BR (1) | BRPI0411126A (pl) |
| CA (1) | CA2527832A1 (pl) |
| DE (1) | DE602004009097T2 (pl) |
| ES (1) | ES2293251T3 (pl) |
| MX (1) | MXPA05013145A (pl) |
| PL (1) | PL1680426T3 (pl) |
| RU (1) | RU2346946C2 (pl) |
| WO (1) | WO2004111055A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| RU2393162C2 (ru) * | 2008-09-12 | 2010-06-27 | Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ (ГОУ ВПО СПХФА Росздрава) | ЗАМЕЩЕННЫЕ 2Н,8Н-1,4-ДИОКСА-9b-АЗАФЕНАЛЕН-2,8-ДИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| RU2498986C2 (ru) * | 2011-07-20 | 2013-11-20 | Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) | ТЕТРАЦИАНОЗАМЕЩЕННЫЕ 1,4,9b-ТРИАЗАФЕНАЛЕНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| CN104945406B (zh) * | 2015-05-25 | 2017-10-10 | 苏州康润医药有限公司 | 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用 |
| CN115894486B (zh) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| PT752813E (pt) * | 1992-09-11 | 2003-04-30 | Univ California | Inibidores de proteases de parasitas metazoarios |
| US5739170A (en) * | 1992-09-11 | 1998-04-14 | The Regents Of The University Of California | Inhibitors of metazoan parasite proteases |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ508154A (en) | 1998-04-29 | 2003-07-25 | Osi Pharm Inc | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| CA2427656A1 (en) * | 2000-11-03 | 2002-05-23 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods relating thereto |
| JP2010532758A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 組み合わせ抗癌療法 |
-
2004
- 2004-04-26 DE DE602004009097T patent/DE602004009097T2/de not_active Expired - Fee Related
- 2004-04-26 EP EP04729442A patent/EP1680426B1/en not_active Expired - Lifetime
- 2004-04-26 CN CNB2004800162458A patent/CN100378101C/zh not_active Expired - Fee Related
- 2004-04-26 BR BRPI0411126-5A patent/BRPI0411126A/pt not_active IP Right Cessation
- 2004-04-26 ES ES04729442T patent/ES2293251T3/es not_active Expired - Lifetime
- 2004-04-26 JP JP2006516102A patent/JP2006527235A/ja active Pending
- 2004-04-26 AT AT04729442T patent/ATE373661T1/de not_active IP Right Cessation
- 2004-04-26 CA CA002527832A patent/CA2527832A1/en not_active Abandoned
- 2004-04-26 WO PCT/EP2004/050608 patent/WO2004111055A1/en not_active Ceased
- 2004-04-26 KR KR1020057023531A patent/KR100753385B1/ko not_active Expired - Fee Related
- 2004-04-26 PL PL04729442T patent/PL1680426T3/pl unknown
- 2004-04-26 AU AU2004247418A patent/AU2004247418B2/en not_active Expired - Fee Related
- 2004-04-26 RU RU2006100034/04A patent/RU2346946C2/ru active
- 2004-04-26 MX MXPA05013145A patent/MXPA05013145A/es active IP Right Grant
- 2004-05-24 US US10/852,735 patent/US7217717B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006100034A (ru) | 2006-08-27 |
| WO2004111055A1 (en) | 2004-12-23 |
| RU2346946C2 (ru) | 2009-02-20 |
| ES2293251T3 (es) | 2008-03-16 |
| KR100753385B1 (ko) | 2007-08-30 |
| ATE373661T1 (de) | 2007-10-15 |
| EP1680426B1 (en) | 2007-09-19 |
| CA2527832A1 (en) | 2004-12-23 |
| EP1680426A1 (en) | 2006-07-19 |
| US20040254205A1 (en) | 2004-12-16 |
| BRPI0411126A (pt) | 2006-07-18 |
| CN100378101C (zh) | 2008-04-02 |
| CN1805964A (zh) | 2006-07-19 |
| AU2004247418A1 (en) | 2004-12-23 |
| US7217717B2 (en) | 2007-05-15 |
| DE602004009097T2 (de) | 2008-06-19 |
| DE602004009097D1 (de) | 2007-10-31 |
| AU2004247418B2 (en) | 2009-11-05 |
| MXPA05013145A (es) | 2006-03-17 |
| JP2006527235A (ja) | 2006-11-30 |
| KR20060017854A (ko) | 2006-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002057261A3 (en) | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase | |
| TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
| GEP20074213B (en) | Novel inhibitors of kinases | |
| IL147271A0 (en) | Compounds that bind her2 | |
| CA2223016A1 (en) | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties | |
| BG106465A (en) | Tyrosine kinase inhibitors | |
| TW200420565A (en) | C-6 modified indazolylpyrrolotriazines | |
| JO2248B1 (en) | Pirazolobenzodiazepines | |
| MY142915A (en) | Rho-kinase inhibitors | |
| UA81658C2 (en) | Substituted pyrimidinones | |
| BRPI0511975A (pt) | pirazolopirimidinas | |
| MY138851A (en) | Quinazoline derivatives | |
| GB0309850D0 (en) | Quinazoline derivatives | |
| PL415000A1 (pl) | Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do wytwarzania leku do leczenia litych guzów ośrodkowego układu nerwowego | |
| DE69907419D1 (en) | Antitumorwirkstoffe | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| TNSN05188A1 (en) | 4-aminopyrimidine-5-one | |
| ATE373661T1 (de) | 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative | |
| DE60224299D1 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| WO2005103034A8 (en) | Novel piperidine substituted diaminothiazoles | |
| TW200612929A (en) | Novel 2,6-diaminopyridine-3-one derivatives | |
| BRPI0511826A (pt) | derivados de 2,4-diaminotiazol-5-ona | |
| WO2003037257A3 (en) | Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 | |
| WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
| WO2001079505A3 (en) | INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY |